search
Back to results

Serranator Recoil Study

Primary Purpose

Peripheral Arterial Disease, Critical Limb Ischemia

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Serranator
POBA
Sponsored by
Cagent Vascular LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Arterial Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female of >18 years old.
  2. Women of childbearing potential must have a negative urine pregnancy test within 7 days of index procedure.
  3. Subject or subject's legal representative has been informed of the nature of the study, agrees to participate, and comply, and has signed the consent form.
  4. Subject has Rutherford Clinical Category 3, 4, 5, or 6.

Angiographic Inclusion Criteria:

  1. Target lesion(s) has stenosis >70% by visual assessment;
  2. De-novo, or non-stented re-stenotic lesions;
  3. Reference vessel diameter is between 2.5 mm and 3.5 mm, inclusive;
  4. Target lesions involve infrapopliteal tibial arteries including pedal;
  5. A target lesion may consist of one long or multiple serial lesions that are up to and including 12 cm in length;
  6. If a second lesion is identified in another vessel, the second lesion can also be treated and if treated will be treated with the alternate treatment.

Exclusion Criteria:

  1. Evidence of aneurysm or acute thrombus in the target vessel.
  2. Subject has an allergy to contrast medium that cannot be pretreated.
  3. Subject is pregnant or breastfeeding.

Angiographic Exclusion Criteria:

  1. Acute Total Occlusions; evidence of acute thrombus formation by angiography.
  2. In-stent restenotic lesions.
  3. Inability to cross the lesion with the assigned study device.
  4. Treatment of target lesion with atherectomy.

Sites / Locations

  • Stanford UniversityRecruiting
  • Klinik für Angiologie, Klinikum Hochsauerland GmbHRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Serranator

POBA

Arm Description

Outcomes

Primary Outcome Measures

Presence of post treatment recoil
Obtain preliminary data on post treatment recoil in infrapopliteal arteries utilizing angiographic and IVUS data following serration angioplasty and standard angioplasty.

Secondary Outcome Measures

Full Information

First Posted
November 19, 2021
Last Updated
June 7, 2022
Sponsor
Cagent Vascular LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT05161039
Brief Title
Serranator Recoil Study
Official Title
Recoil Feasibility Study for the Treatment of Atherosclerotic Lesions in the Infrapopliteal Arteries Comparing Serration Angioplasty (Serranator® Device) vs. Plain Balloon Angioplasty (POBA)
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 15, 2021 (Actual)
Primary Completion Date
July 2022 (Anticipated)
Study Completion Date
July 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cagent Vascular LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study objective is to assess the ability to define and measure post treatment recoil in infrapopliteal arteries. Preliminary evidence as to the differences between serration angioplasty and standard balloon angioplasty as defined by post treatment recoil, lumen gain, and dissection will be collected.
Detailed Description
Multi-center, feasibility study treating up to 20 atherosclerotic lesions in the infrapopliteal arteries. The study will capture angiographic imaging (pre, during, post, and post 15 mins) for all lesions, and a subset (up to 10) of IVUS imaging data (pre, post, and post 15 mins), to compare serration angioplasty vs standard angioplasty and its effects on vessel recoil and final diameter stenosis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease, Critical Limb Ischemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Serranator
Arm Type
Other
Arm Title
POBA
Arm Type
Other
Intervention Type
Device
Intervention Name(s)
Serranator
Intervention Description
Serranator® PTA Serration Balloon Catheter manufactured by Cagent Vascular
Intervention Type
Device
Intervention Name(s)
POBA
Intervention Description
Plain balloon angioplasty device
Primary Outcome Measure Information:
Title
Presence of post treatment recoil
Description
Obtain preliminary data on post treatment recoil in infrapopliteal arteries utilizing angiographic and IVUS data following serration angioplasty and standard angioplasty.
Time Frame
15 minutes post procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female of >18 years old. Women of childbearing potential must have a negative urine pregnancy test within 7 days of index procedure. Subject or subject's legal representative has been informed of the nature of the study, agrees to participate, and comply, and has signed the consent form. Subject has Rutherford Clinical Category 3, 4, 5, or 6. Angiographic Inclusion Criteria: Target lesion(s) has stenosis >70% by visual assessment; De-novo, or non-stented re-stenotic lesions; Reference vessel diameter is between 2.5 mm and 3.5 mm, inclusive; Target lesions involve infrapopliteal tibial arteries including pedal; A target lesion may consist of one long or multiple serial lesions that are up to and including 12 cm in length; If a second lesion is identified in another vessel, the second lesion can also be treated and if treated will be treated with the alternate treatment. Exclusion Criteria: Evidence of aneurysm or acute thrombus in the target vessel. Subject has an allergy to contrast medium that cannot be pretreated. Subject is pregnant or breastfeeding. Angiographic Exclusion Criteria: Acute Total Occlusions; evidence of acute thrombus formation by angiography. In-stent restenotic lesions. Inability to cross the lesion with the assigned study device. Treatment of target lesion with atherectomy.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Robert Giasolli
Phone
610.688.2006
Email
rgiasolli@cagentvascular.com
Facility Information:
Facility Name
Stanford University
City
Palo Alto
State/Province
California
ZIP/Postal Code
94305
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Venita Chandra, MD
Facility Name
Klinik für Angiologie, Klinikum Hochsauerland GmbH
City
Arnsberg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stefan Stahlhoff, MD

12. IPD Sharing Statement

Learn more about this trial

Serranator Recoil Study

We'll reach out to this number within 24 hrs